首页> 美国卫生研究院文献>ClinicoEconomics and Outcomes Research: CEOR >Societal savings in patients with advanced non-squamous non-small-cell lung cancer receiving bevacizumab-based versus non-bevacizumab-based treatments in France Germany Italy and Spain

【2h】

Societal savings in patients with advanced non-squamous non-small-cell lung cancer receiving bevacizumab-based versus non-bevacizumab-based treatments in France Germany Italy and Spain

机译：在法国德国意大利和西班牙接受基于贝伐单抗和非贝伐单抗治疗的晚期非鳞状非小细胞肺癌晚期患者的社会节省

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundThe purpose of this study was to investigate the savings accrued using bevacizumab-based treatment for non-small-cell lung cancer from the societal perspective, taking only public costs into account, in France, Germany, Italy, and Spain.

机译：背景本研究的目的是从社会角度研究基于贝伐单抗的非小细胞肺癌治疗所产生的节省，在法国，德国，意大利和西班牙仅考虑公共费用。

著录项

期刊名称 ClinicoEconomics and Outcomes Research: CEOR
作者
Johanna Lister; Sanja Stanisic; Klaus Kaier; Christian Hagist; Dmitry Gultyaev; Stefan Walzer;
展开▼
作者单位

展开▼
年(卷),期 2012(4),-1
年度 2012
页码 299–305
总页数 7
原文格式 PDF
正文语种
中图分类
关键词
non-small-cell lung cancer bevacizumab chemotherapy economic model France Germany Italy Spain;

机译：非小细胞肺癌;贝伐单抗;化学疗法;经济模型;法国;德国;意大利;西班牙;

相似文献

外文文献
中文文献
专利

1. Societal savings in patients with advanced non-squamous non-small-cell lung cancer receiving bevacizumab-based versus non-bevacizumab-based treatments in France, Germany, Italy, and Spain [J] . Johanna Lister, Sanja Stanisic, Klaus Kaier, ClinicoEconomics and Outcomes Research . 2012,第10期

机译：在法国，德国，意大利和西班牙接受基于贝伐单抗和非贝伐单抗治疗的晚期非鳞状非小细胞肺癌晚期患者的社会节省
2. First-Liee Bevacizumab-Based Therapy in Advanced Non-Squamous Non-Small-Cell Lung Cancer-Analysis of the Italian Patients Enrolled in the SAiL Study [J] . Alessra Bearz, Rodolfo Passalacqua, Oscar Alabiso, Clinical drug investigation . 2012,第11期

机译：基于贝伐单抗的一线治疗在晚期非鳞状非小细胞肺癌中的作用-对参与SAiL研究的意大利患者的分析
3. Comparison of treatment costs of grade 3/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and Spain. [J] . Banz K, Bischoff H, Brunner M, Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2011,第3期

机译：在德国，法国，意大利和西班牙比较晚期厄立替尼或培美曲塞维持治疗对3/4级不良事件的治疗费用。
4. Pemetrexed versus docetaxel single agent chemotherapy in chemotherapy-naive elderly patients with advanced non-small cell lung cancer [C] . Hua Xin, Zhenguo Han, Haibo Huang 2011 International Conference on Human Health and Biomedical Engineering . 2011

机译：培美曲塞与多西他赛单药化疗在未接受化疗的老年晚期非小细胞肺癌患者中的作用
5. Level of hope in patients receiving medical treatment for the diagnosis of lung cancer. [D] . Milone, Mary Anne. 2010

机译：接受药物治疗以诊断肺癌的患者的希望水平。
6. The present and future burden of previously treated advanced non-small cell lung cancer (NSCLC) by histology and line of therapy in France Germany Italy and Spain: model-based predictions [O] . David Campbell, Ken O’Day, Nadine Hertel, 2018

机译：在法国德国意大利和西班牙通过组织学和疗法分类先前治疗的晚期非小细胞肺癌（NSCLC）的当前和未来负担：基于模型的预测
7. Societal savings in patients with advanced non-squamous non-small-cell lung cancer receiving bevacizumab-based versus non-bevacizumab-based treatments in France, Germany, Italy, and Spain [O] . Lister J., Stanisic S., Kaier K., 2012

机译：在法国，德国，意大利和西班牙接受基于贝伐单抗和非贝伐单抗治疗的晚期非鳞状非小细胞肺癌患者的社会储蓄

Societal savings in patients with advanced non-squamous non-small-cell lung cancer receiving bevacizumab-based versus non-bevacizumab-based treatments in France Germany Italy and Spain

摘要

著录项

相似文献

相关主题

期刊订阅